Search

Your search keyword '"Kilbourne, Jacquelyn"' showing total 32 results
Start Over Author "Kilbourne, Jacquelyn" Search Limiters Full Text
32 results on '"Kilbourne, Jacquelyn"'

4. Nuclear Export Inhibitor Selinexor Enhances Oncolytic Myxoma Virus Therapy against Cancer

Author

Rahman, Masmudur M., primary, van Oosterom, Fleur, additional, Enow, Junior A., additional, Hossain, Maksuda, additional, Gutierrez-Jensen, Ami D., additional, Cashen, Mackenzie, additional, Everts, Anne, additional, Lowe, Kenneth, additional, Kilbourne, Jacquelyn, additional, Daggett-Vondras, Juliane, additional, Karr, Timothy L., additional, and McFadden, Grant, additional

Published
2023
Full Text
View/download PDF

6. Immune protection is dependent on the gut microbiome in a lethal mouse gammaherpesviral infection

Author

Yaron, Jordan R., Ambadapadi, Sriram, Zhang, Liqiang, Chavan, Ramani N., Tibbetts, Scott A., Keinan, Shahar, Varsani, Arvind, Maldonado, Juan, Kraberger, Simona, Tafoya, Amanda M., Bullard, Whitney L., Kilbourne, Jacquelyn, Stern-Harbutte, Alison, Krajmalnik-Brown, Rosa, Munk, Barbara H., Koppang, Erling O., Lim, Efrem S., and Lucas, Alexandra R.

Published
2020
Full Text
View/download PDF

7. Virus-Derived Chemokine Modulating Protein Pre-Treatment Blocks Chemokine–Glycosaminoglycan Interactions and Significantly Reduces Transplant Immune Damage

Author

Zanetti, Isabela R., primary, Burgin, Michelle, additional, Zhang, Liqiang, additional, Yeh, Steve T., additional, Ambadapadi, Sriram, additional, Kilbourne, Jacquelyn, additional, Yaron, Jordan R., additional, Lowe, Kenneth M., additional, Daggett-Vondras, Juliane, additional, Fonseca, David, additional, Boyd, Ryan, additional, Wakefield, Dara, additional, Clapp, William, additional, Lim, Efrem, additional, Chen, Hao, additional, and Lucas, Alexandra, additional

Published
2022
Full Text
View/download PDF

8. Transplantation of autologous bone marrow pre-loaded ex vivo with oncolytic myxoma virus is efficacious against drug-resistant Vk*MYC mouse myeloma

Author

Villa, Nancy Y., primary, Rahman, Masmudur M., additional, Mamola, Joseph, additional, Sharik, Meaghen E., additional, de Matos, Ana Lemos, additional, Kilbourne, Jacquelyn, additional, Lowe, Kenneth, additional, Daggett-Vondras, Juliane, additional, D'Isabella, Julia, additional, Goras, Elizabeth, additional, Chesi, Marta, additional, Bergsagel, P. Leif, additional, and McFadden, Grant, additional

Published
2022
Full Text
View/download PDF

10. Plant-derived human butyrylcholinesterase, but not an organophosphorous-compound hydrolyzing variant thereof, protects rodents against nerve agents

Author

Geyer, Brian C., Kannan, Latha, Garnaud, Pierre-Emmanuel, Broomfield, Clarence A., Cadieux, C. Linn, Cherni, Irene, Hodgins, Sean M., Kasten, Shane A., Kelley, Karli, Kilbourne, Jacquelyn, Oliver, Zeke P., Otto, Tamara C., Puffenberger, Ian, Reeves, Tony E., Robbins, Neil, Woods, Ryan R., Soreq, Hermona, Lenz, David E., Cerasoli, Douglas M., Mor, Tsafrir S., and Arntzen, Charles J.

Published
2010

11. Systemic Delivery of mLIGHT-Armed Myxoma Virus Is Therapeutic for Later-Stage Syngeneic Murine Lung Metastatic Osteosarcoma

Author

Christie, John D., primary, Appel, Nicole, additional, Zhang, Liqiang, additional, Lowe, Kenneth, additional, Kilbourne, Jacquelyn, additional, Daggett-Vondras, Juliane, additional, Elliott, Natalie, additional, Lucas, Alexandra R., additional, Blattman, Joseph N., additional, Rahman, Masmudur M., additional, and McFadden, Grant, additional

Published
2022
Full Text
View/download PDF

13. Systemic delivery of TNF-armed myxoma virus plus immune checkpoint inhibitor eliminates lung metastatic mouse osteosarcoma

Author

Christie, John D., primary, Appel, Nicole, additional, Canter, Hannah, additional, Achi, Jazmin Galvan, additional, Elliott, Natalie M., additional, de Matos, Ana Lemos, additional, Franco, Lina, additional, Kilbourne, Jacquelyn, additional, Lowe, Kenneth, additional, Rahman, Masmudur M., additional, Villa, Nancy Y., additional, Carmen, Joshua, additional, Luna, Evelyn, additional, Blattman, Joseph, additional, and McFadden, Grant, additional

Published
2021
Full Text
View/download PDF

15. Gene Regulatory Network Analysis and Engineering Directs Development and Vascularization of Multilineage Human Liver Organoids

Author

Velazquez, Jeremy J., primary, LeGraw, Ryan, additional, Moghadam, Farzaneh, additional, Tan, Yuqi, additional, Kilbourne, Jacquelyn, additional, Maggiore, Joseph C., additional, Hislop, Joshua, additional, Liu, Silvia, additional, Cats, Davy, additional, Chuva de Sousa Lopes, Susana M., additional, Plaisier, Christopher, additional, Cahan, Patrick, additional, Kiani, Samira, additional, and Ebrahimkhani, Mo R., additional

Published
2021
Full Text
View/download PDF

17. Recombinant Myxoma Virus-Derived Immune Modulator M-T7 Accelerates Cutaneous Wound Healing and Improves Tissue Remodeling

Author

Yaron, Jordan R., primary, Zhang, Liqiang, additional, Guo, Qiuyun, additional, Awo, Enkidia A., additional, Burgin, Michelle, additional, Schutz, Lauren N., additional, Zhang, Nathan, additional, Kilbourne, Jacquelyn, additional, Daggett-Vondras, Juliane, additional, Lowe, Kenneth M., additional, and Lucas, Alexandra R., additional

Published
2020
Full Text
View/download PDF

18. Autologous Transplantation Using Donor Leukocytes Loaded Ex Vivo with Oncolytic Myxoma Virus Can Eliminate Residual Multiple Myeloma

Author

Villa, Nancy.Y., primary, Rahman, Masmudur M., additional, Mamola, Joseph., additional, D’Isabella, Julia, additional, Goras, Elizabeth, additional, Kilbourne, Jacquelyn, additional, Lowe, Kenneth, additional, Daggett-Vondras, Juliane, additional, Torres, Lino, additional, Christie, John, additional, Appel, Nicole, additional, Cox, Anna L., additional, Kim, Jae B., additional, and McFadden, Grant, additional

Published
2020
Full Text
View/download PDF

20. Corrigendum to “A heterologous prime-boosting strategy with replicating Vaccinia virus vectors and plant-produced HIV-1 Gag/dgp41 virus-like particles” [Virology 507 (2017) 242–256]

Author

Meador, Lydia R., primary, Kessans, Sarah A., additional, Kilbourne, Jacquelyn, additional, Kibler, Karen V., additional, Pantaleo, Giuseppe, additional, Esteban, Mariano, additional, Blattman, Joseph N., additional, Jacobs, Bertram L., additional, and Mor, Tsafrir S., additional

Published
2019
Full Text
View/download PDF

29. Inflammatory Effects of Edwardsiella ictaluriLipopolysaccharide Modifications in Catfish Gut

Author

Santander, Javier, Kilbourne, Jacquelyn, Park, Jie-Yeun, Martin, Taylor, Loh, Amanda, Diaz, Ignacia, Rojas, Robert, Segovia, Cristopher, DeNardo, Dale, and Curtiss, Roy

Abstract

ABSTRACTBacterial lipopolysaccharides (LPS) are structural components of the outer membranes of Gram-negative bacteria and also are potent inducers of inflammation in mammals. Higher vertebrates are extremely sensitive to LPS, but lower vertebrates, like fish, are resistant to their systemic toxic effects. However, the effects of LPS on the fish intestinal mucosa remain unknown. Edwardsiella ictaluriis a primitive member of the Enterobacteriaceaefamily that causes enteric septicemia in channel catfish (Ictalurus punctatus). E. ictaluriinfects and colonizes deep lymphoid tissues upon oral or immersion infection. Both gut and olfactory organs are the primary sites of invasion. At the systemic level, E. ictaluripathogenesis is relatively well characterized, but our knowledge about E. ictaluriintestinal interaction is limited. Recently, we observed that E. ictalurioligo-polysaccharide (O-PS) LPS mutants have differential effects on the intestinal epithelia of orally inoculated catfish. Here we evaluate the effects of E. ictaluriO-PS LPS mutants by using a novel catfish intestinal loop model and compare it to the rabbit ileal loop model inoculated with Salmonella entericaserovar Typhimurium LPS. We found evident differences in rabbit ileal loop and catfish ileal loop responses to E. ictaluriand S. Typhimurium LPS. We determined that catfish respond to E. ictaluriLPS but not to S. Typhimurium LPS. We also determined that E. ictaluriinhibits cytokine production and induces disruption of the intestinal fish epithelia in an O-PS-dependent fashion. The E. ictaluriwild type and ?wibTLPS mutant caused intestinal tissue damage and inhibited proinflammatory cytokine synthesis, in contrast to E. ictaluri?gneand ?ugdLPS mutants. We concluded that the E. ictaluriO-PS subunits play a major role during pathogenesis, since they influence the recognition of the LPS by the intestinal mucosal immune system of the catfish. The LPS structure of E. ictalurimutants is needed to understand the mechanism of interaction.

Published
2014
Full Text
View/download PDF

30. A Virus-Derived Immune Modulating Serpin Accelerates Wound Closure with Improved Collagen Remodeling.

Author

Zhang, Liqiang, Yaron, Jordan R., Tafoya, Amanda M., Wallace, Sarah E., Kilbourne, Jacquelyn, Haydel, Shelley, Rege, Kaushal, McFadden, Grant, and Lucas, Alexandra R.

Subjects
PLASMINOGEN activators, COLLAGEN, WOUND healing, WOUNDS & injuries, PROTEASE inhibitors
Abstract

Numerous treatments have been developed to promote wound healing based on current understandings of the healing process. Hemorrhaging, clotting, and associated inflammation regulate early wound healing. We investigated treatment with a virus-derived immune modulating serine protease inhibitor (SERPIN), Serp-1, which inhibits thrombolytic proteases and inflammation, in a mouse excisional wound model. Saline or recombinant Serp-1 were applied directly to wounds as single doses of 1 μg or 2 µg or as two 1 µg boluses. A chitosan-collagen hydrogel was also tested for Serp-1 delivery. Wound size was measured daily for 15 days and scarring assessed by Masson's trichrome, Herovici's staining, and immune cell dynamics and angiogenesis by immunohistochemistry. Serp-1 treatment significantly accelerated wound healing, but was blocked by urokinase-type plasminogen activator (uPAR) antibody. Repeated dosing at a lower concentration was more effective than single high-dose serpin. A single application of Serp-1-loaded chitosan-collagen hydrogel was as effective as repeated aqueous Serp-1 dosing. Serp-1 treatment of wounds increased arginase-1-expressing M2-polarized macrophage counts and periwound angiogenesis in the wound bed. Collagen staining also demonstrated that Serp-1 improves collagen maturation and organization at the wound site. Serp-1 has potential as a safe and effective immune modulating treatment that targets thrombolytic proteases, accelerating healing and reducing scar in deep cutaneous wounds. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

31. Systemic delivery of TNF-armed myxoma virus plus immune checkpoint inhibitor eliminates lung metastatic mouse osteosarcoma.

Author

Christie JD, Appel N, Canter H, Achi JG, Elliott NM, de Matos AL, Franco L, Kilbourne J, Lowe K, Rahman MM, Villa NY, Carmen J, Luna E, Blattman J, and McFadden G

Abstract

Solid cancers that metastasize to the lungs represent a major therapeutic challenge. Current treatment paradigms for lung metastases consist of radiation therapy, chemotherapies, and surgical resection, but there is no single treatment or combination that is effective for all tumor types. To address this, oncolytic myxoma virus (MYXV) engineered to express human tumor necrosis factor (vMyx-hTNF) was tested after systemic administration in an immunocompetent mouse K7M2-Luc lung metastatic osteosarcoma model. Virus therapy efficacy against pre-seeded lung metastases was assessed after systemic infusion of either naked virus or ex vivo -loaded autologous bone marrow leukocytes or peripheral blood mononuclear cells (PBMCs). Results of this study showed that the PBMC pre-loaded strategy was the most effective at reducing tumor burden and increasing median survival time, but sequential intravenous multi-dosing with naked virus was comparably effective to a single infusion of PBMC-loaded virus. PBMC-loaded vMyx-hTNF also potentially synergized very effectively with immune checkpoint inhibitors anti-PD-1, anti-PD-L1, and anti-cytotoxic T lymphocyte associated protein 4 (CTLA-4). Finally, in addition to the pro-immune stimulation caused by unarmed MYXV, the TNF transgene of vMyx-hTNF further induced the unique expression of numerous additional cytokines associated with the innate and adaptive immune responses in this model. We conclude that systemic ex vivo virotherapy with TNF-α-armed MYXV represents a new potential strategy against lung metastatic cancers like osteosarcoma and can potentially act synergistically with established checkpoint immunotherapies., Competing Interests: G.M. is co-founder and equity holder of OncoMyx Therapeutics. J.D.C. and M.M.R. are consultants for OncoMyx Therapeutics. The remaining authors declare no competing interests., (© 2021 The Author(s).)

Published
2021
Full Text
View/download PDF

32. Autologous Transplantation Using Donor Leukocytes Loaded Ex Vivo with Oncolytic Myxoma Virus Can Eliminate Residual Multiple Myeloma.

Author

Villa NY, Rahman MM, Mamola J, D'Isabella J, Goras E, Kilbourne J, Lowe K, Daggett-Vondras J, Torres L, Christie J, Appel N, Cox AL, Kim JB, and McFadden G

Abstract

Multiple myeloma (MM) is a hematological malignancy of monoclonal plasma cells that remains incurable. Standard treatments for MM include myeloablative regimens and autologous cell transplantation for eligible patients. A major challenge of these treatments is the relapse of the disease due to residual MM in niches that become refractory to treatments. Therefore, novel therapies are needed in order to eliminate minimal residual disease (MRD). Recently, our laboratory reported that virotherapy with oncolytic myxoma virus (MYXV) improved MM-free survival in an allogeneic transplant mouse model. In this study, we demonstrate the capacity of donor autologous murine leukocytes, pre-armed with MYXV, to eliminate MRD in a BALB/c MM model. We report that MYXV-armed bone marrow (BM) carrier leukocytes are therapeutically superior to MYXV-armed peripheral blood mononuclear cells (PBMCs) or free virus. Importantly, when cured survivor mice were re-challenged with fresh myeloma cells, they developed immunity to the same MM that had comprised MRD. In vivo imaging demonstrated that autologous carrier cells armed with MYXV were very efficient at delivery of MYXV into the recipient tumor microenvironment. Finally, we demonstrate that treatment with MYXV activates the secretion of pro-immune molecules from the tumor bed. These results highlight the utility of exploiting autologous leukocytes to enhance tumor delivery of MYXV to treat MRD in vivo ., (© 2020 The Author(s).)

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results